Company: NCEL
Filing Date: 2025-09-10
Form Type: 424B3
Source: 0001213900-25-086600
Chunk: 269

Company: NewcelX Ltd.
Filing Date: 2025-09-10
Form: 424B3
Chunk 269
---
 Vote is required. You may vote “FOR,” “AGAINST” or “ABSTAIN” on Proposal 5. A failure to vote, an abstention or a broker non -vote, if any, will have the same effect as a vote “AGAINST” Proposal 5. THE NLS BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE
“FOR” PROPOSAL 5. 114 APPROVAL OF INCREASE OF THE CONDITIONAL SHARE CAPITALS FOR SHAREHOLDERS’ OPTIONS (PROPOSAL 6) Under Swiss law, our shareholders, by a Supermajority Vote, may empower the NLS Board to issue shares of a specific aggregate nominal amount up to a maximum of 50% of the share capital in the form of conditional capital for the purpose of issuing shares in connection with, among other things, (i) option and conversion rights granted in connection with warrants and convertible bonds of NLS or one of our subsidiaries or (ii) grants of rights to employees, directors or consultants or our subsidiaries or other persons providing services to NLS or a subsidiary to subscribe for new shares (conversion or option rights). At the extraordinary shareholders’ meeting, shareholders will be asked to approve the increase of the conditional share capital for employee and advisory options (including RSUs) (3b) of the Company to the maximum amount of (currently) CHF 27,000 (Proposal 5 above) and the increase of the conditional share capital for shareholders’ options (3c) of the Company to the maximum amount of (currently) CHF 88,146.66 (this Proposal 6). We are bringing this proposal to our shareholders to approve that the conditional share capital for shareholders’ options (in accordance with article 3c paragraph 1 of the Articles) shall be equal to the maximum amount permitted by law (i.e., in the amount of one -halfof the new share capital to be calculated on the day of the NLS Meeting less the amount of the conditional share capital for employee and advisory options of the Company (article 3b paragraph 1 of the Articles)). The increase of share capital for shareholders’ options is required to enable the consummation of the Merger Agreement. At the Effective Time each option, restricted share unit, restricted share, warrant or other rights issued and outstanding, whether vested or unvested, to purchase Kadimastem Ordinary Shares, shall be assumed by NLS and converted into an option, warrant, other award,